David Joseph Topper, the Chief Financial Officer of Arcutis Biotherapeutics, has filed an Initial Statement of Beneficial Ownership of Securities with the SEC, as per Form 3. The filing, dated April 10, 2024, indicates that Topper beneficially owns non-derivative securities and has vested stock options in the company. Specifically, Topper has the right to buy 7,500 shares of common stock at an exercise price of $2.54 per share, with the option exercisable until December 18, 2033. The form was signed by Topper's attorney-on-fact, Masaru Matsuda, on April 11, 2024. This filing is a routine disclosure required by corporate officers to report their securities holdings in the company, in compliance with Section 16(a) of the Securities Exchange Act of 1934.

David Joseph Topper, the Chief Financial Officer of Arcutis Biotherapeutics, has filed an Initial Statement of Beneficial Ownership of Securities with the SEC, as per Form 3. The filing, dated April 10, 2024, indicates that Topper beneficially owns non-derivative securities and has vested stock options in the company. Specifically, Topper has the right to buy 7,500 shares of common stock at an exercise price of $2.54 per share, with the option exercisable until December 18, 2033. The form was signed by Topper's attorney-on-fact, Masaru Matsuda, on April 11, 2024. This filing is a routine disclosure required by corporate officers to report their securities holdings in the company, in compliance with Section 16(a) of the Securities Exchange Act of 1934.